We’re teaming up with POLITICO Europe to host a debate on the importance of striking the right balance between incentivizing innovation and supporting access to medicine in Europe’s intellectual property (IP) system. 📢 A well-balanced IP system should reward medical innovation with a period of patent protection, before opening doors for generic and biosimilar competition, which lowers cost and expands patient access to new medicines. Patent protections must be fair, and the system must mitigate anti-competitive evergreening practices aimed at extending exclusivity. With generics and biosimilars making up 70% of essential medicines in Europe, a thriving off-patent medicines sector is key to a sustainable healthcare ecosystem. It is imperative to have this discussion and evolve IP frameworks for the future of patient care in Europe. Read more and register through the link below to join the debate 👇 #PharmaPatentsEU
On April 10, POLITICO Live’s Oxford-Style Debate will convene two expert teams who will compete to determine whether the EU strikes the right balance between incentivizing innovation and ensuring patient access. Apply to join us onsite: https://ow.ly/ZXZ850VlpB7 | #PharmaPatentsEU